Oncternal Therapeutics (NASDAQ: ONCT)
$8.54
(-2.5%)
-$0.22
Price as of April 24, 2024, 1:13 p.m. ET
Oncternal Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Oncternal Therapeutics Company Info
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.
Valuation
Earnings Transcripts
Oncternal Therapeutics, Inc. (ONCT) Q2 2022 Earnings Call Transcript
ONCT earnings call for the period ending June 30, 2022.
Motley Fool Transcribing | Aug 10, 2022
Oncternal Therapeutics, Inc. (ONCT) Q1 2022 Earnings Call Transcript
ONCT earnings call for the period ending March 31, 2022.
Motley Fool Transcribing | May 6, 2022
Oncternal Therapeutics, Inc. (ONCT) Q4 2021 Earnings Call Transcript
ONCT earnings call for the period ending December 31, 2021.
Motley Fool Transcribing | Mar 10, 2022
Oncternal Therapeutics, Inc. (ONCT) Q3 2021 Earnings Call Transcript
ONCT earnings call for the period ending September 30, 2021.
Motley Fool Transcribing | Nov 5, 2021
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.